CoChat
Sign Up
Cited by 114Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Diabetes and Cardiovascular Disease: an Update

Almourani, Rajaa, Chinnakotla, Bhavana, Patel, Richa, Kurukulasuriya, L. Romayne, Sowers, James·2019·Current Diabetes Reports
DOI 10.1007/s11892-019-1239-x
Open this paper in CoChat — free account

Abstract

Purpose of review Cardiovascular disease (CVD) is the leading cause of mortality in people with diabetes. Our aim was to review the pathophysiology of CVD in diabetes, review related landmark trials, and discuss the cardiovascular benefit of glucose-lowering agents. We have also discussed the role of controversial anti-platelet therapy. Recent findings Recent studies have shown the impact of glucose-lowering agents on CVD in people with diabetes. Statins are now recommended for all patients with diabetes over the age of 40 regardless of the LDL level given the cardiovascular benefit of these drugs. Current recommendations suggest a blood pressure < 130/80 for individuals with high cardiovascular risk. Cardiovascular risk reduction should be an important part of the management of diabetes. Focusing solely on glycemic control may not be the best therapeutic strategy. Multifactorial risk reduction should be taken into account. Lipid-lowering agents and anti-hypertensives should be a corner stone of treatment of diabetes. With currently available data, glucose-lowering agents with cardiovascular benefit should be started early in the disease process.

Integrity signals

Registry

Crossref · 10.1007/s11892-019-1239-x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CVD is the leading cause of death among individuals with diabetes, with complications such as heart attacks and strokes being major contributors to diabetes-related morbidity and mortality.

    “CVD is the leading cause of death among individuals with diabetes, with complications such as heart attacks and strokes being major contributors to diabetes-related morbidity and mortality (98).”

    From Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review (2025) · cites this paper as [98]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J.
Affiliations
  • University of Missouri (US)
  • Harry S. Truman Memorial Veterans' Hospital (US)
Corresponding author
  • Kurukulasuriya, L. Romayne
  • Sowers, James
ORCID
Venue
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Published
2019-12
Volume
19
Issue
12
Pages
161-161
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
DOI
10.1007/s11892-019-1239-x
OpenAlex
W2995560091
Cited by
114
References
27
Citations by year
2026: 10 · 2025: 16 · 2024: 14 · 2023: 33 · 2022: 22 · 2021: 8 · 2020: 10 · 2018: 1
FWCI
1.58
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
diabetes mellitus, cardiovascular disease, pathophysiology, glucose-lowering agents, statins, antiplatelet therapy, blood pressure targets, cardiovascular risk reduction, lipid-lowering drugs, antihypertensive drugs, glycemic control, cardiovascular mortality
MeSH terms
Hypolipidemic Agents, Blood Glucose, Cardiovascular Diseases, Humans, Hypertension, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review